Risk of second cancers cancer after a first primary breast cancer: A systematic review and meta-analysis

Molina‐Montes, Esther; Requena, Mar; Sánchez‐Cantalejo, Emilio; Fernández, Mariana F.; Arroyo-Morales, Manuel; Espín, Jaime; Arrebola, Juan Pedro; Sánchez, María‐José

doi:10.1016/j.ygyno.2014.10.029

Cited by 95 publications

(109 citation statements)

References 48 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…19 Our estimate of the overall risk of a second cancer among patients with breast cancer is consistent with that analysis. As in previous studies, we found that although all women with breast cancer experience an increased risk of second primary cancer, younger women have a greater excess risk for a second primary cancer than the general population of women of the same age.…”

Section: Discussionsupporting

confidence: 88%

Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006

Silverman

Lipshitz

Keinan‐Boker

2017

JGO

View full text Add to dashboard Cite

PurposeImprovements in early detection and treatment have resulted in improved long-term survival from breast cancer, which increases the likelihood of the occurrence of second primary cancers. We calculated the risk of second primary cancers among Israeli women receiving a first primary breast cancer diagnosis.MethodsBy using data from the Israel National Cancer Registry, we identified 46,090 women with invasive breast cancer diagnosed between 1990 and 2006 and non–breast primary cancers diagnosed subsequent to breast cancer diagnosis. We used life table analysis to calculate the risk of a second primary cancer and calculated standardized incidence ratios (SIRs) by using age-specific cancer risk in the general population of Israeli women as the standard and stratifying by diagnosis period (1992 to 1996, 1997 to 2001, 2002 to 2006) and age at diagnosis (< 50 and ≥ 50 years).ResultsThe probability of a second malignancy was 3.6% within 5 years, 8.2% within 10 years, and 13.9% within 15 years. The SIR for any second non–breast primary cancer was 1.26 (95% CI, 1.23 to 1.30). Significantly increased risks of colorectal, uterine, lung, ovarian, and thyroid cancer and leukemia were observed for the full follow-up period, which persisted after excluding the first 6 months after index diagnosis, although increased leukemia and colorectal cancer risks were no longer statistically significant. Women younger than age 50 years at initial diagnosis had a greater excess risk than women age 50 years and older (SIR, 1.77 [95% CI, 1.63 to 1.91] and 1.20 [95% CI, 1.15 to 1.24], respectively).ConclusionThe findings likely reflect a combination of personal risk factors (genetics, hormonal therapy, environmental exposures) as well as the effects of the initial cancer treatment and are unlikely to be explained by enhanced surveillance alone.

show abstract

Section: Discussionsupporting

confidence: 88%

Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006

Silverman

Lipshitz

Keinan‐Boker

2017

JGO

View full text Add to dashboard Cite

show abstract

“…Women younger than 50 years have a 51% increase in risk in comparison to an 11% increase in women aged over 50 years. Furthermore, the risk of second malignancy after breast cancer is increased by 19% within the first 10 years and by 26% after 10 years [15].…”

Section: Discussionmentioning

confidence: 99%

“…The risk of second primaries also depends on patient age and the amount of time elapsed since anticancer therapy [3,4,[14][15][16]. According to data published by Lee et al, the 30-year overall cumulative incidence of second malignancies amounts to 5.2% for children (aged ≤ 14 years), 13.9% for adolescents and young adults (aged 15-39 years) and 16.8% for adults (aged ≥ 40 years) [4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The characteristics of breast cancer patients with metachronous primary malignancies

Sas-Korczyńska¹,

Kamzol²,

Kołodziej-Rzepa³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Introduction. The risk of developing subsequent primary cancers varies from 1% to 18% and it depends on the type of first cancer and treatment methods applied. Considering the time of occurrence, multiple primary cancers generally fall into two categories: synchronous and metachronous. In breast cancer patients, 10.5% developed multiple primary cancers, from which 23.8% had synchronous, 79% had metachronous and the remaining 2.8% had both synchronous and metachronous malignancies. In patients with breast cancer, elevated risk is observed especially in the development of contralateral breast cancer, endometrial cancer, esophageal cancer, ovarian cancer and thyroid cancer. Aim. This paper presented the characteristics of breast cancer patients with metachronous primary malignancies in relation to the type of metachronous primaries (breast versus non-breast) and to analyse the impact of the type of metachronous cancers on survival rate. Material and methods. Among patients treated for breast cancer between 1963 and 2010, 354 patients (2.1%) developed metachronous primary malignancies and these made up 13.8% of all patients with multiple primary cancers. The mean age at diagnosis of the first breast cancer was 53 ± 11.5 years; positive family cancer history was noted in 127 patients (35.9%). Metachronous malignancies are defined as primaries following the diagnosis of breast cancer in a time interval greater than or equal to than 6 months. In our group, the mean time interval between the diagnosis of breast cancer and the appearance of metachronous malignancies was 100.9 ± 74.9 months (range: 6-543 months, median: 83 months). For comparison of the two groups (patients with second breast vs non-breast cancer) we used the Pearson's Chi-square test for independence (for categorized variables) and variance analysis with Student's t-test (for continuous variables). The survival rate was evaluated with the Kaplan-Meier method, and the log rank test was applied to assess the influence of some factors on the evaluated results. The significance level at α = 0.05 was adopted for all statistical analyses. Results. The probability of occurrence of new cancer averaged from 38.1% to 67.8% for 5 and 10 years after diagnosis of first breast cancer, respectively. In our group, 380 cases of metachronous carcinomas were noted in 354 analysed patients. The most frequent metachronous malignancy was breast cancer (194 cases -54.8%), which occurred as second (192 cases) or third (2 cases) cancer. Patients with contralateral breast cancer in comparison to other types of metachronous malignancies were significantly (p < 0.05): younger (under 50 years: 56.2% vs 34.4%), premenopausal (69.6% vs 48.8%), had a lobular type of first breast cancer (6.7% vs 1.3%), and rarely received tamoxifen (25.3% vs 48.2%). The type of metachronous cancers significantly influenced survival rate: 10-year overall survival rates were 80.1% vs 67.8%, (p = 0.0271). Conclusions. The risk of occurrence of second malignancies in breast cancer survivors makes early dete...

show abstract

“…Из 710 статей, опубликованных по этой проблеме к июню 2013 г., авторы отобрали 15, коррект-но отражающих результаты ретроспективных когорт-ных исследований. Метаанализ объединенных ре-зультатов выявил повышенный на 17 % по сравнению со здоровыми женщинами риск вторых опухолей раз-личных локализаций, за исключением РМЖ [19].…”

Section: обзорные статьиunclassified

Second primary malignancies in cancer survivors: epidemiology, role of anticancer therapy

Соленова¹

2016

Usp. mol. onkol

View full text Add to dashboard Cite

Успехи в ранней диагностике и лечении злокаче-ственных новообразований (ЗН) привели к более дли-тельной продолжительности жизни онкологических больных, что является индикатором эффективности системы здравоохранения в целом. В России 5-летняя выживаемость онкологических больных выросла с 49,1 % в 1998 г. до 52,9 % в 2015 г. [1,2]. Эти данные совпадают с европейскими, согласно которым средняя 5-летняя выживаемость в 1988-1999 гг. немного превышала 50 % [3]. Данные самого большого кооперативного иссле-дования в Европе (EUROCARE) свидетельствуют об из-менениях в диагностике, лечении ЗН, а также в реа-билита ции онкологических больных, что существенно повлияло на их выживаемость. С 1999-2001 по 2005-2007 гг. значительные успехи были достигнуты в вы-живаемости больных раком предстательной железы (81,7 %), неходжкинской лимфомой (НХЛ) (60,4 %), раком прямой кишки (57,6 %). Показатели сильно ва-

show abstract

Risk of second cancers cancer after a first primary breast cancer: A systematic review and meta-analysis

Cited by 95 publications

References 48 publications

Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006

Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006

The characteristics of breast cancer patients with metachronous primary malignancies

Second primary malignancies in cancer survivors: epidemiology, role of anticancer therapy

Contact Info

Product

Resources

About